Skip to main content

Advertisement

SpringerLink
Log in

Explorative immunohistochemical study to evaluate the addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis

  • Short Communication
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

The aim of this study was to explore the additional effect of betamethasone dipropionate cream in the early phase of an intramuscular (IM) alefacept course, on plaque severity and on modulating T-cell subsets, cells expressing NK-receptors, epidermal proliferation and keratinocyte differentiation in lesional psoriatic skin. Therefore, sixteen patients with moderate-to-severe chronic plaque psoriasis received 15 mg alefacept IM for 12 weeks, followed by a 12-week follow-up period. The first 4 weeks, patients were randomized 1:1 to either betamethasone dipropionate, or the vehicle cream, once daily. Plaque severity (SUM) was assessed and serial biopsies were immunohistochemically stained for T-cell subsets (CD3, CD4, CD8, CD45RO, CD45RA, CD2, CD25, GITR), cells expressing NK-receptors (CD94 and CD161), epidermal proliferation (Ki67) and differentiation (K10), which were quantified using manual and digital image analysis. Alefacept monotherapy resulted in statistically significant improvement in plaque severity. Subsequently, immunohistochemical assessments on T-cell subsets, epidermal proliferation (Ki67) and keratinization (K10) revealed marked time-related improvements with respect to the mentioned parameters, without significant differences between both treatment regimens. Alefacept monotherapy induces improvement of plaque severity, which is accompanied by a reduction in activated (CD2+, CD25+, CD45RO+) dermal CD4+ and activated epidermal CD8+ T cells, epidermal proliferation and differentiation. Once daily treatment with betamethasone dipropionate cream during the first 4 weeks of an intramuscular alefacept course did not provide substantial additional clinical and immunohistochemical improvement.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

References

  1. Ashwell JD, Lu FW, Vacchio MS (2000) Glucocorticoids in T cell development and function. Annu Rev Immunol 18: 309–345

    Article  PubMed  CAS  Google Scholar 

  2. Bos JD, De Rie MA, Teunissen MB, Piskin G (2005) Psoriasis: dysregulation of innate immunity. Br J Dermatol 152: 1098–1107

    Article  PubMed  CAS  Google Scholar 

  3. Bovenschen HJ, Gerritsen WJ, De Jong EM, Van de Kerkhof. PC. Addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis. Acta Derm Venereol (in press)

  4. Bovenschen HJ, Seyger MM, Van de Kerkhof PC (2005) Plaque psoriasis vs. atopic dermatitis and lichen planus: a comparison for lesional T-cell subsets, epidermal proliferation and differentiation. Br J Dermatol 153:72–78

    Article  PubMed  CAS  Google Scholar 

  5. Bovenschen HJ, Vissers WH, Seyger MM, Van de Kerkhof PC (2005) Selective persistence of dermal CD8+ T cells in lesional plaque psoriasis after clobetasol-17 propionate treatment. Acta Derm Venereol 85:113–117

    Article  PubMed  CAS  Google Scholar 

  6. Chamian F, Lowes MA, Lin S-L, Lee E, Kikuchi T, Gilleaudeau P, Sullivan-Whalen M, Cardinale I, Khatcherian A, Novitskaya I, Wittkowski KM, Krueger JG (2005) Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci USA 102:2075–2080

    Article  PubMed  CAS  Google Scholar 

  7. De Jong EM, Ferrier CM, de Zwart A, Wauben-Penris PJ, Korstanje C, Van de Kerkhof PC (1995) Effects of topical treatment with budesonide on parameters for epidermal proliferation, keratinization and inflammation in psoriasis. J Dermatol Sci 9:185–194

    Article  PubMed  Google Scholar 

  8. Eisman S, Rustin MH (2003) Corticosteroids. In: Van de Kerkhof PCM (ed) Textbook of psoriasis 2nd edn. Blackwell, Oxford

    Google Scholar 

  9. Ellis CN, Krueger GG (2001) Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 345:248–255

    Article  PubMed  CAS  Google Scholar 

  10. Fisher LB, Maibach HI (1971) The effect of corticosteroids on human epidermal mitotic activity. Arch Dermatol 103:39–41

    Article  PubMed  CAS  Google Scholar 

  11. Frederiksson T, Petterson U (1978) Severe psoriasis—oral therapy with a new retinoid. Dermatologica 157:238–244

    Article  Google Scholar 

  12. Goedkoop AY, de Rie MA, Picavet DI, Kraan MC, Dinant HJ, van Kuijk AW, Tak PP, Bos JD, Teunissen MB (2004) Alefacept therapy reduces the effector T-cell population in lesional psoriatic epidermis. Arch Dermatol Res 295:465–473

    Article  PubMed  CAS  Google Scholar 

  13. Gordon KB, Vaishnaw AK, O’Gorman J, Haney J, Menter A (2003) Treatment of psoriasis with alefacept. Correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol 139:1563–1570

    Article  PubMed  CAS  Google Scholar 

  14. Gottlieb AB, Casale TB, Frankel E, Goffe B, Lowe N, Ochs HD, Roberts JL, Washenik K, Vaishnaw AK, Gordon KB (2003) CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J Am Acad Dermatol 49:816–825

    Article  PubMed  Google Scholar 

  15. Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H (2004) Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol 135:1–8

    Article  PubMed  CAS  Google Scholar 

  16. Krueger JG, Gilleaudeau P, Kikuchi T, Lee E. (2002) Alefacept selectively reduces subpopulations of memory CD4+ and CD8+ T cells (Abstract). J Invest Dermatol 119:759

    Google Scholar 

  17. Krueger JG (2002) The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 46:1–23

    Article  PubMed  Google Scholar 

  18. Krueger GG (2003) Clinical response to alefacept: results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2 (suppl 17):17–24

    Article  Google Scholar 

  19. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN; Alefacept Clinical Study Group (2002) A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 47:821–833

    Article  PubMed  Google Scholar 

  20. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CE; Alefacept Clinical Study Group (2003) An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 139:719–727

    Article  PubMed  CAS  Google Scholar 

  21. Majeau GR, Meier W, Jimmo B, Kioussis D, Hochman PS (1994) Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice. J Immunol 152:2753–2767

    PubMed  CAS  Google Scholar 

  22. Miller GT, Hochman PS, Meier W, Tizard R, Bixler SA, Rosa MD, Wallner BP (1993) Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med 178:211–222

    Article  PubMed  CAS  Google Scholar 

  23. Nickoloff BJ (1999) The immunologic and genetic basis of psoriasis. Arch Dermatol 135:1104–10

    Article  PubMed  CAS  Google Scholar 

  24. Nickoloff BJ, Bonish B, Huang BB, Porcelli SA (2000) Characterization of a T cell line bearing natural killer receptors and capable of creating psoriasis in a SCID mouse model. J Dermatol Sci 24:212–225

    Article  PubMed  CAS  Google Scholar 

  25. Ortonne JP (2003) Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J Eur Acad Dermatol Venereol 2 (suppl 17):12–16

    Article  Google Scholar 

  26. Van der Vleuten CJ, Van Vlijmen-Willems IM, De Jong EM, Van de Kerkhof PC (1999) Clobetasol-17 propionate lotion under hydrocolloid dressing (Duoderm ET) once weekly versus unoccluded clobetasol-17-propionate ointment twice daily in psoriasis: an immunohistochemical study on remission and relapse. Arch Dermatol Res 291:390–395

    Article  PubMed  Google Scholar 

  27. Vissers WH, Berends M, Muys L, Van Erp PE, De Jong EM, Van de Kerkhof PC (2004) The effect of the combination of calcipotriol and betamethasone dipropionate versus both monotherapies on epidermal proliferation, keratinization and T-cell subsets in chronic plaque psoriasis. Exp Dermatol 13:106–112

    Article  PubMed  CAS  Google Scholar 

  28. Vissers WH, Van Duijnhoven MW, Van Erp PE, De Jong EM, Van de Kerkhof PC (2005) The effect of alefacept on T-cell subsets and cells expressing NK-receptors in lesional psoriatic skin; effects of monotherapy and combination treatment with calcipotriol cream (Submitted)

  29. Vissers WH, Arndtz CH, Muys L, Van Erp PE, de Jong EM, van de Kerkhof PC (2004) Memory effector (CD45RO+) and cytotoxic (CD8+) T cells appear early in the margin zone of spreading psoriatic lesions in contrast to cells expressing natural killer receptors, which appear late. Br J Dermatol 150:852–859

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, Nijmegen, 6500 HB, The Netherlands

    H. J. Bovenschen, W. J. Gerritsen, D. W. A. van Rens, M. M. B. Seyger, E. M. G. J. de Jong & P. C. M. van de Kerkhof

Authors
  1. H. J. Bovenschen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. J. Gerritsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. D. W. A. van Rens
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. M. B. Seyger
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. M. G. J. de Jong
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P. C. M. van de Kerkhof
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H. J. Bovenschen.

Additional information

This IRT study was funded by a grant from Biogen Inc Europe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bovenschen, H.J., Gerritsen, W.J., van Rens, D.W.A. et al. Explorative immunohistochemical study to evaluate the addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis. Arch Dermatol Res 298, 457–463 (2007). https://doi.org/10.1007/s00403-006-0716-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00403-006-0716-7

Keywords

Search

Navigation